Axitinib after Treatment Failure with Sunitinib or Cytokines in Advanced Renal Cell Carcinoma-Systematic Literature Review of Clinical and Real-World Evidence.
Anand SharmaAmit BahlRicky FrazerEsha GodhaniaNicholas HalfpennyKristina HartlDorothea HeldtJohn McGraneSera Şahbaz GülserBalaji VenugopalAimi RitchieKatherine CrichtonPublished in: Cancers (2024)
Axitinib is commonly used in clinical practice and has a well-characterised safety and efficacy profile in the treatment of patients with aRCC after the failure of prior therapy with sunitinib or cytokines.